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Objectives: Trials comparing addition of simeprevir (SMV) or placebo to peginter-
feron/ribavirin for treatment of chronic hepatitis C virus (HCV) infection found that 
all patient-reported outcome (PRO) measures except Absenteeism scores from the 
Work Productivity and Activity Impairment questionnaire for Hepatitis C (WPAI:HepC) 
showed similar patterns over time and significantly better outcomes for the SMV groups. 
Absenteeism scores using recommended scoring were available only if a patient was 
in the workforce at baseline and subsequent study visits. To appreciate movement into 
and/or out of the workforce in HCV trials, we propose two alternative scores for the 
WPAI:HepC: Missed Work and Work Impairment. MethOds: A total of 711 subjects com-
pleted the WPAI:HepC in the QUEST1 and QUEST2 SMV trials during study visits at base-
line and throughout treatment and follow-up. The WPAI:HepC assesses whether subjects 
were in the workforce during the past 7 days; and if so, number of hours missed from 
work due to HCV or its treatment/number of hours scheduled to work (Absenteeism); 
and how much productivity was impaired when working (Productivity Impairment). 
Revised scoring produced Missed Work scores (% hours not working in past week) and 
Work Impairment (Missed Work x Productivity Impairment) for all subjects at each study 
visit by setting scores for subjects not in the workforce to 100 (range 0 to 100% Missed 
Work or Work Impairment). Results: WPAI Missed Work score results showed modest 
differences between treatments but Work Impairment scores were significantly better 
for the SMV group with a pattern over time consistent with other PRO endpoints in the 
trials (p= 0.034). cOnclusiOns: Methods for evaluating impact of HCV treatment on 
work life in clinical trials need to provide data for all subjects in order to capture work 
force participation and productivity when working. Revised scoring of the WPAI:HepC 
enable more accurate comparison of treatment in clinical trials.
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Objectives: It is well recognized that HPV infection causes a substantial burden 
in females. The infection also causes a substantial burden in males as it is associ-
ated with HPV-related cancers. Traditional economic evaluations focus only on 
quantifying cost-effectiveness, however, it is increasingly recognized that immuni-
zations may generate broader benefits not captured in cost-effectiveness analysis. 
This research aimed at developing a government-perspective health investment 
model to estimate the fiscal impact of immunizing males and females with the 
quadrivalent HPV vaccine in Germany. MethOds: Methodologies from genera-
tional accounting, human capital and health economics were combined to esti-
mate the fiscal benefits of HPV immunization. Cohort models were developed 
simulating the medical costs and average lifetime fiscal transfers between the 
government and cohorts of 13-year-old immunized and non-immunized indi-
viduals. To estimate tax revenue attributed to immunization-related changes in 
morbidity and mortality, direct and indirect tax rates were linked to differences 
in age- and gender-specific earnings. Results: The lifetime discounted gross tax 
for the immunized male and female cohorts (n= 400,000 each) were € 208.7 billion 
and € 130.4 billion, respectively. Over the lifetime of the female and male birth-
cohorts, it was estimated that immunization with the quadrivalent HPV vaccine 
would result in the prevention of 986 female and 296 male HPV-related deaths. 
Compared to the non-immunized cohorts of 13-year old males and females, the 
immunized cohorts resulted in higher total net discounted tax by € 106.1 million 
and higher total gross discounted tax by € 80.4 million. cOnclusiOns: The com-
bined vaccination of males and females in Germany results in positive lifetime net 
and gross discounted tax revenues for the government. The vaccination of males 
and females with the quadrivalent HPV vaccine is likely to have positive effects 
on public finances and economic growth over subsequent generations.
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Objectives: To date, efforts to model Clostridium difficile infection (CDI) have 
been limited. Most models do not address the contribution of asymptomatic carri-
ers as sources of new infections and are restricted to hospital acquired CDI. We aim 
to develop a simulation model to systematically examine the dynamic relationship 
between three major subpopulations of CDI transmission: hospitals, communities, 
and long-term facilities, to evaluate treatment effectiveness and costs. MethOds: 
We conducted a systematic investigation to determine the key epidemiological 
factors influencing CDI transmission according to the three major subpopula-
tions: hospitals, communities, and long-term care facilities. We have developed a 
stochastic agent-tracking meta-population network model of CDI transmission, 
and identified parameters that would capture transmission from symptomatic 
and asymptomatic carriers to uninfected individuals among the subpopula-
tions. Results: We identified eight infection states: susceptible, gastrointestinal 
exposure, colonized, diseased, deceased, clinically resolved colonized, relapse of 
CDI, and cleared. Key parameters include; health outcomes of target populations, 
time horizon, diagnostic characteristics, treatment effectiveness, transmission 
rates, susceptibility rates, recurrence rates, and costs. Initial treatments of CDI 
do not induce a lasting response in 15%-25% of patients. The estimated effective-
ness of antibiotic therapy for a first recurrence is 60% and declining with multiple 
recurrences. Major predictors of recurrences were advanced age and duration of 
initial hospitalizations. Recurrences of CDI were associated with major increases 
in hospital LOS and costs. cOnclusiOns: Our dynamic network model of CDI 
transmission will improve the capacity to project and to quantify the impact of a 
CDI outbreak in terms of clinical burden and costs.
Receiver Operating Characteristics (ROC) curves correlating HCV-PRO score to MID 
anchors on SF–36 MCS/PCS and EQ-5D VAS. Results: Demographics (N= 74): 22% 
female, 81% white, 51% > 50 years of age, 74% Genotype 1a, 69% IL28B non-CC 
status. Convergent validity: HCV-PRO total score correlations with SF-36 MCS/
PCS and EQ-5D VAS scores were 0.64-0.93 (all time points). Discriminant valid-
ity: HCV-PRO scores decreased 10-30 points more in subjects impaired by anxi-
ety/depression (EQ-5D) or experiencing depression/fatigue events. ES showed an 
increasing impact during treatment (-0.66, week 8; -0.76, EODT; –0.93, EOT). At 
PT24, ES returned to -0.10. SEM and ROC analyses suggested an HCV-PRO MID 
approximating -10 points. cOnclusiOns: The HCV-PRO is a valid, responsive, 
disease-specific instrument. In this study, an MID of approximately -10 points 
was identified. The HCV-PRO may enhance understanding of how HCV treatment 
impacts function/wellbeing.
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Objectives: Neurocognitive impairment (NCI), depression, and duration of unem-
ployment have been reported as barriers to obtaining employment among people liv-
ing with HIV/AIDS (PLWHA) in the US. However, upon return to work, improvements in 
depression and health-related quality of life (HRQoL) have been observed. The objec-
tives of this study were to examine the burden of unemployment among PLWHA in 
Canada and Europe by 1.) estimating the number of PLWHA who are unemployed and 
their duration of unemployment, and (2) determining patient characteristics associ-
ated with being unemployed, including NCI, depression, and HRQoL. MethOds: Data 
was derived from CRANIum (sCReen for Anxiety, depression, and Neurocognitive 
Impairment in HIV+ patients), a multicenter, cross-sectional study of PLWHA in 14 
European countries and Canada between 2010 and 2011. Depression was assessed 
using the Hospital Anxiety and Depression Scale. NCI was assessed using the Brief 
Neurocognitive Screen, which consists of the Digit Symbol (DS) test and Trail Making 
tests A and B. HRQoL was assessed using the Medical Outcomes Study HIV Health 
Survey (MOS-HIV). Logistic regression was utilized in order to determine if these 
variables, in addition to demographic and clinical variables, were associated with 
unemployment. Results: A total of 2754 PLWHA (mean age = 43; 62% male) were 
included in these analyses; 960 (35%) were unemployed. Regarding the unemployed, 
110 (11%) had been unemployed for < 6 months, 99 (10%) for 6 to 12 months, and 737 
(77%) for > 12 months. Logistic regression analyses indicated that NCI, lower scores on 
the MOS-HIV physical health subscale, previous psychiatric diagnoses, lesser educa-
tion, Hepatitis B and/or C co-infection, older age and female gender were indepen-
dently associated with unemployment. Current depression was not associated with 
unemployment. cOnclusiOns: In tandem with previous reports, results from this 
multinational study suggest that NCI and HRQoL are salient issues with regards to 
employment among PLWHA internationally.
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Objectives: Chronic HCV infection and interferon-based treatments negatively 
impact PROs. The HCV-PRO is a validated disease-specific PRO instrument for patients 
with HCV. The purpose of this analysis was to ascertain the psychometric properties of 
the German-translated HCV-PRO. MethOds: Responses from German subjects to the 
HCV-PRO, SF-36v.2, and EQ-5D 5L+VAS were analyzed from the multinational AVIATOR 
trial of interferon-free oral DAA therapy in Genotype 1 patients. HCV-PRO was trans-
lated under Harmonization standards. Approved German-language validated ver-
sions of the SF-36 and EQ-5D were included for psychometric comparison. Internal 
consistency/reliability of HCV-PRO items and total score (range 0–100) were evaluated 
using Chronbach’s alpha. Convergent validity of HCV-PRO total score was assessed 
through Pearson’s correlation to SF-36 MCS/PCS and EQ-5D VAS scores (0.5–0.9 = 
moderate–strong). Discriminant validity was assessed by dichotomizing HCV-PRO 
total score on EQ-5D Anxiety/Depression and Pain/Discomfort dimensions by severity 
(none vs. some). Response range of HCV-PRO total score was examined. Analyses were 
performed at Baseline, week 8 (Wk8), End of Treatment (EOT), and 24 week follow-up 
(PTW24). Results: Demographics (N= 39): 46% female, 97% white, 46% ≥ 50 years 
of age, 36% Genotype 1a, 87% IL28B non-CC status. Clinical response was 92.3% of 
German patients achieving SVR24. Mean HCV-PRO, SF-36 MCS/PCS, and EQ-5D VAS 
scores were minimally changed during treatment (Wk8, EOT). Cronbach’s alpha for 
HCV-PRO items and total scores over time were 0.92–0.96. HCV-PRO total score exhib-
ited moderate-to-high correlation with SF-36 MCS/PCS and EQ-5D VAS total scores 
at each time period (r= 0.42–0.85), with highest correlation with SF-36 MCS. HCV-PRO 
mean scores were lower in subjects with anxiety/depression or pain/discomfort vs. 
none (p< 0.01). Mean HCV-PRO score at PTW24 was improved (p= 0.038) over baseline. 
Baseline HCV-PRO floor (0%) and ceiling (10%) scores were acceptable. cOnclusiOns: 
The German-translated HCV-PRO is a valid, responsive, disease-specific instrument 
for German-speaking HCV-infected people.
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